Ibrutinib, a first-generation BTK inhibitor, is the first targeted therapy approved for the management of patients with relapsed and/or refractory (R/R) CLL in February 2014, with an overall response rate (ORR) of 71% [6]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.